POCI

Business Context and Reporting Period

Company: Precision Optics Corporation, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: The Company designs and manufactures advanced optical instruments, including micro-optics, medical instruments (laparoscopes, arthroscopes, endocouplers), and 3-D endoscopes. It utilizes proprietary technologies such as Lenslock and micro-precision lens systems. The Company is a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 41.8% ($355,516) for the quarter and 25.2% ($545,263) for the nine months compared to the prior year periods. This was driven by lower unit sales of endocouplers, rigid endoscopes, and advanced surgical visualization systems.
• Margin Compression: Gross profit margin for the quarter dropped from 43.1% to 27.1%, and for the nine months from 38.2% to 35.9%, primarily due to lower sales volume.
• Increased R&D Expenses: Research and Development expenses increased 15.6% for the quarter and 89.5% for the nine months, attributed to higher labor/material costs and decreased customer reimbursements.
• Reduced SG&A: Selling, General, and Administrative expenses decreased 13.6% for the quarter and 21.2% for the nine months due to reduced executive salaries and the settlement of deferred compensation liabilities via stock issuance.
• Interest Expense Reduction: Interest expense decreased 76.9% for both periods due to the full amortization of the debt discount on the Senior Secured Convertible Notes in the prior fiscal year.
• Cash Position: Cash and cash equivalents decreased from $416,040 (June 30, 2010) to $39,570 (March 31, 2011), a net decrease of $376,470 over the nine-month period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management states there is substantial doubt about the Company's ability to continue as a going concern. The Company predicts it will not have sufficient cash to continue operations for the next three months without additional funding.
• Debt Maturity: The $600,000 principal and $165,833 accrued interest on the 10% Senior Secured Convertible Notes are due June 3, 2011. The Company expects holders may convert the debt to equity, but there is no guarantee. Failure to pay or refinance could lead to bankruptcy.
• Deferred Compensation Settlement: The Company agreed to settle $674,645 of deferred officer salaries and director consulting fees by issuing 245,326 shares of restricted common stock rather than cash.
• Internal Control Weaknesses: The Company disclosed material weaknesses regarding segregation of duties (due to limited accounting staff) and inventory valuation. Remediation steps include higher-level reviews by the President and Board.
• Outlook: Management expects operating losses to continue until sales increase to breakeven levels. Future success depends on the commercialization of new products (Lenslock endoscopes, micro-precision lenses) and securing additional capital.

Investor Verification Checklist

• Liquidity Crisis: Verify the Company's ability to raise capital immediately to cover the $765,833 debt obligation due June 3, 2011, and sustain operations beyond the next three months.
• Debt Conversion: Confirm whether holders of the Senior Secured Convertible Notes have elected to convert principal and interest into common stock to avoid default.
• Revenue Recovery: Assess the validity of management's projections regarding new product sales (Lenslock, micro-precision) required to achieve profitability.
• Stock Dilution: Review the impact of the 245,326 shares issued for deferred compensation and potential future equity issuances for capital raising.
• Internal Controls: Evaluate the effectiveness of the remediation steps taken for material weaknesses in segregation of duties and inventory valuation.